These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 28705697

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK.
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
    Wilding J, Bailey C, Rigney U, Blak B, Kok M, Emmas C.
    Prim Care Diabetes; 2017 Oct; 11(5):437-444. PubMed ID: 28583425
    [Abstract] [Full Text] [Related]

  • 27. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D, Italian Study Group on the Diffusion of CSII.
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [Abstract] [Full Text] [Related]

  • 28. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
    Datta-Nemdharry P, Thomson A, Beynon J, Donegan K.
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
    [Abstract] [Full Text] [Related]

  • 29. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R, Node K, Hanafusa T, Atsumi Y, Naito Y, Oka Y.
    Cardiovasc Diabetol; 2013 Sep 08; 12():131. PubMed ID: 24011395
    [Abstract] [Full Text] [Related]

  • 30. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.
    van Dieren S, Kengne AP, Chalmers J, Beulens JW, Davis TM, Fulcher G, Heller SR, Patel A, Colagiuri S, Hamet P, Mancia G, Marre M, Neal B, Williams B, Peelen LM, van der Schouw YT, Woodward M, Zoungas S.
    Diabetes Obes Metab; 2014 May 08; 16(5):426-32. PubMed ID: 24251579
    [Abstract] [Full Text] [Related]

  • 31. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J, Yates CJ, Blackberry I, Furler J, Ginnivan L, Cohen N, Jenkins A, Vasanthakumar S, Gorelik A, Young D, Best J, O'Neal D.
    Diabet Med; 2016 Jun 08; 33(6):803-11. PubMed ID: 26435033
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Development and validation of a computer application to aid the physician's decision-making process at the start of and during treatment with insulin in type 2 diabetes: a randomized and controlled trial.
    Sáenz A, Brito M, Morón I, Torralba A, García-Sanz E, Redondo J.
    J Diabetes Sci Technol; 2012 May 01; 6(3):581-8. PubMed ID: 22768889
    [Abstract] [Full Text] [Related]

  • 35. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L, Pan C, Wang H, Bertolini M, Lew E, Meneghini LF.
    Diabetes Obes Metab; 2018 Apr 01; 20(4):831-839. PubMed ID: 29119712
    [Abstract] [Full Text] [Related]

  • 36. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, Home PD.
    Diabetes Obes Metab; 2015 Sep 01; 17(9):835-42. PubMed ID: 25846721
    [Abstract] [Full Text] [Related]

  • 37. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
    Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW, OpT2mise Study Group.
    Lancet; 2014 Oct 04; 384(9950):1265-72. PubMed ID: 24998009
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM.
    Cardiovasc Diabetol; 2012 Nov 15; 11():142. PubMed ID: 23153177
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.